RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Fudan University Shanghai Cancer Center; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT04997837, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Postoperative histologically confirmed adenocarcinoma of the stomach or GEJ

    Inclusion criterion 4

  3. Positive lymph nodes more than 7, stage pN3

    Inclusion criterion 5

  4. Patients after standard D2/R0 resection

    Inclusion criterion 3

  5. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1

    Inclusion criterion 1

  6. Patients' blood routine and biochemical indicators should meet the following standard: Hb≥90g/L, ANC≥1.5*10\^9/L, PLT≥100*10\^9/L, ALT \& AST≤2.5 U/L, TB ≤ 1.5 UNL, serum creatinine<1 UNL.

    Inclusion criterion 8

  7. Patient diagnosed with other malignant tumor in the past 5 years, excluding radical basal cell carcinoma of the skin and/or radical resected carcinoma in situ.

    Exclusion criterion 7

    Patient with known HIV infection, or active tuberculosis.

    Exclusion criterion 11

    Patient with active HCV infection

    Exclusion criterion 13

  8. Pregnant or lactation period

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04997837, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1
  • Patients with expected survival time more than 6 months
  • Patients after standard D2/R0 resection
  • Postoperative histologically confirmed adenocarcinoma of the stomach or GEJ
  • Positive lymph nodes more than 7, stage pN3
  • Patients without distant metastasis (M0) or M1 with abdominal exfoliated cell detection positive (CY1P0)
  • Patients' physical condition and visceral function allows following adjuvant therapy, including chemotherapy, chemoradiotherapy and PD-1 inhibitor therapy.
  • Patients' blood routine and biochemical indicators should meet the following standard: Hb≥90g/L, ANC≥1.5*10\^9/L, PLT≥100*10\^9/L, ALT \& AST≤2.5 U/L, TB ≤ 1.5 UNL, serum creatinine<1 UNL.
  • Patients who are willing to obey regimens during the study.
  • Written informed consent is acquired before random entry, and patients should know that he/she has the right to quit, and following treatment won't be affected.
  • Patients are willing to provide samples of blood and tissue.

Exclusion Criteria:

  • Patients with gross peritoneal metastasis (CY1P0 excluded) or distant metastasis.
  • Patients who has received any anti-tumor therapy before surgery.
  • Patients who had received radiotherapy for abdominal organs including stomach, liver, kidney, etc.
  • Patients who had active systematic autoimmune diseases which need systematic treatment within 2 years before first medication in the study, substitutive therapy (such as thyroxine, insulin, etc) excluded.
  • Patients diagnosed with immunodeficiency, or was receiving systematic glucocorticoid treatment or other immunosuppressive therapy within 7 days before medication, physiological dose of glucocorticoid is allowed (≤10 mg/d prednison or equivalent medication)
  • Patients who have known severe allergic reaction (≥level 3) to anti-PD-1 monoclonal antibody, 5-FU, Oxaliplatin or any auxiliary material.
  • Patient diagnosed with other malignant tumor in the past 5 years, excluding radical basal cell carcinoma of the skin and/or radical resected carcinoma in situ.
  • Patient with severe vital organ failure.
  • Pregnant or lactation period
  • Patient with known mental illness or drug abuse that may influence compliance.
  • Patient with known HIV infection, or active tuberculosis.
  • Untreated active hepatitis B
  • Patient with active HCV infection
  • Uncontrolled complications
  • Other situations that might disturb study results and compliance.

Quoted from ClinicalTrials.gov, NCT04997837, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT04997837, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT04997837